(42) developed an “Immuno-organoid” platform by co-culturing patient-derived organoids (PDOs) with autologous peripheral blood mononuclear cells (PBMCs) or tumor-infiltrating lymphocytes (TILs), supplemented with key cytokines (IL-2, IL-15, IFN-γ) to maintain immune cell viability. The gene discussed is IL2; the disease is neoplasm.